Engineering physiologically regulated insulin secretion in non-β cells by expressing glucagon-like peptide 1 receptor

Gene Therapy

Volumn 10, Issue 19, 2003, Pages 1712-1720

  Wu, L ^a   Nicholson, W ^a   Wu, C Y ^a   Xu, M ^a   McGaha, A ^a   Shiota, M ^b   Powers, Al C ^a,b,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adenoviral vector; Insulin secretion; Pancreatic islets; Pituitary cells

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HORMONE RECEPTOR; HYPOPHYSIS HORMONE; HYPOTHALAMUS RELEASING FACTOR; INSULIN; MESSENGER RNA;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL TRANSPLANTATION; CONTROLLED STUDY; DOSE RESPONSE; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HYPOPHYSIS CELL; INSULIN RELEASE; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REGULATORY MECHANISM; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GLUCOSE; HUMANS; INSULIN; MALE; MICE; MICE, INBRED NOD; MICE, SCID; PITUITARY GLAND; PITUITARY HORMONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; STIMULATION, CHEMICAL; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA;

EID: 0042412563     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302055     Document Type: Article

References (49)

1. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967; 46: 1954-1962.
2. Creutzfeldt M. Candidate hormones of the gut. XV. Insulin-releasing factors of the gastrointestinal mucosa (Incretin). Gastroenterology 1974; 67: 748-750.
3. Holst JJ. Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic Potential. Trends Endocrinol Metab 1999; 10: 229-235.
4. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001; 142: 521-527.
5. Thorens B. Glucagon-like peptide-1 and control of insulin secretion. Diabetes Metab 1995; 21: 311-318.
6. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco- incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992; 89: 8641-8645.
7. Thorens B, Waeber G. Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM. Diabetes 1993; 42: 1219-1225.
8. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995; 16: 390-410.
9. Sherwood NM, Krueckl SL, McRory JE. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 2000; 21: 619-670.
10. 2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37). J Biol Chem 1999; 274: 14147-14156.
11. Meglasson MD, Matschinsky FM. Pancreatic islet glucose metabolism and regulation of insulin secretion. Diabetes Metab Rev 1986; 2: 163-214.
12. Fehmann HC et al. The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets. Pancreas 1995; 11: 196-200.
13. Yamada S et al. Time-dependent stimulation of insulin exocytosis by 3′,5′-cyclic adenosine monophosphate in the rat islet beta-cell. Endocrinology 2002; 143: 4203-4209.
14. Dachicourt N et al. Glucagon-like peptide-1(7-36)-amide confers glucose sensitivity to previously glucose-incompetent beta-cells in diabetic rats: in vivo and in vitro studies. J Endocrinol 1997; 155: 369-376.
15. Gutniak M et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 326: 1316-1322.
16. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 1994; 93: 2263-2266.
17. Ahren B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 473-478.
18. Nauck MA et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
19. Clark SA et al. Novel insulinoma cell lines produced by iterative engineering of GLUT2, glucokinase, and human insulin expression. Diabetes 1997; 46: 958-967.
20. Hohmeier HE et al. Regulation of insulin secretion from novel engineered insulinoma cell lines. Diabetes 1997; 46: 968-977.
21. Ferber S et al. Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nat Med 2000; 6: 568-572.
22. Lee HC et al. Remission in models of type 1 diabetes by gene therapy using a single- chain insulin analogue. Nature 2000; 408: 483-488.
23. Chen R, Meseck M, McEvoy RC, Woo SL. Glucose-stimulated and self-limiting insulin production by glucose 6-phosphatase promoter driven insulin expression in hepatoma cells. Gene Therapy 2000; 7: 1802-1809.
24. Tooze SA. Biogenesis of secretory granules. Implications arising from the immature secretory granule in the regulated pathway of secretion. FEBS Lett 1991; 285: 220-224.
25. Tooze SA, Martens GJ, Huttner WB. Secretory granule biogenesis: rafting to the SNARE. Trends Cell Biol 2001; 11: 116-122.
26. Zhu X et al. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc Natl Acad Sci USA 2002; 99: 10293-10298.
27. Zhu X et al. Severe block in processing of proinsulin to insulin accompanied by elevation of des-64,65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3. Proc Natl Acad Sci USA 2002; 99: 10299-10304.
28. Beak SA et al. Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells. Endocrinology 1996; 137: 4130-4138.
29. Taniguchi Y, Yasutaka S, Kominami R, Shinohara H. Proliferation and differentiation of rat anterior pituitary cells. Anat Embryol (Berl) 2002; 206: 1-11.
30. Kendall SK et al. Targeted disruption of the pituitary glycoprotein hormone alpha-subunit produces hypogonadal and hypothyroid mice. Genes Dev 1995; 9: 2007-2019.
31. Castro MG et al. Expression of transgenes in normal and neoplastic anterior pituitary cells using recombinant adenoviruses: long term expression, cell cycle dependency, and effects on hormone secretion. Endocrinology 1997; 138: 2184-2194.
32. Holz GGt, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 1993; 361: 362-365.
33. Hui H, Yu R, Bousquet C, Perfetti R. Transfection of pancreatic-derived beta-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion. Endocrinology 2002; 143: 3529-3539.
34. Kolligs F, Fehmann HC, Goke R, Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 1995; 44: 16-19.
35. Efrat S et al. Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene. Proc Natl Acad Sci USA 1995; 92: 3576-3580.
36. Lipes MA et al. Insulin-secreting non-islet cells are resistant to autoimmune destruction. Proc Natl Acad Sci USA 1996; 93: 8595-8600.
37. Faradji RN et al. Glucose-induced toxicity in insulin-producing pituitary cells that coexpress GLUT2 and glucokinase. Implications for metabolic engineering. J Biol Chem 2001; 276: 36695-36702.
38. Kolodka TM, Finegold M, Moss L, Woo SL. Gene therapy for diabetes mellitus in rats by hepatic expression of insulin. Proc Natl Acad Sci USA 1995; 92: 3293-3297.
39. Gros L et al. Insulin production by engineered muscle cells. Hum Gene Ther 1999; 10: 1207-1217.
40. Falqui L et al. Reversal of diabetes in mice by implantation of human fibroblasts genetically engineered to release mature human insulin. Hum Gene Ther 1999; 10: 1753-1762.
41. Hughes SD, Johnson JH, Quaade C, Newgard CB. Engineering of glucose-stimulated insulin secretion and biosynthesis in nonislet cells. Proc Natl Acad Sci USA 1992; 89: 688-692.
42. Hughes SD et al. Transfection of AtT-20ins cells with GLUT-2 but not GLUT-1 confers glucose-stimulated insulin secretion. Relationship to glucose metabolism. J Biol Chem 1993; 268: 15205-15012.
43. Lu M, Wheeler MB, Leng XH, Boyd AEd. The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7-37). Endocrinology 1993; 132: 94-100.
44. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995; 358: 219-224.
45. Wu L, Fritz JD, Powers AC. Different functional domains of GLUT2 glucose transporter are required for glucose affinity and substrate specificity. Endocrinology 1998; 139: 4205-4212.
46. Watanabe T, Orth DN. Detailed kinetic analysis of adrenocorticotropin secretion by dispersed rat anterior pituitary cells in a microperifusion system: effects of ovine corticotropin-releasing factor and arginine vasopressin. Endocrinology 1987; 121: 1133-1145.
47. Openshaw P et al. Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. J Exp Med 1995; 182: 1357-1367.
48. Wang T et al. An encapsulation system for the immunoisolation of pancreatic islets. Nat Biotechnol 1997; 15: 358-362.
49. Hartling SG et al. ELISA for human proinsulin. Clin Chim Acta 1986; 156: 289-297.